Neurocrine Biosciences (NBIX) Other Non-Current Assets (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Other Non-Current Assets for 17 consecutive years, with $59.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Assets rose 174.54% year-over-year to $59.3 million; the trailing twelve-month figure through Jun 2026 stood at $59.3 million (up 174.54% YoY), and the FY2025 full-year result was $48.7 million, down 6.35% from the prior year.
• Other Non-Current Assets fell to $59.3 million in Q2 2026 per NBIX's latest filing, from $73.6 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $73.6 million in Q1 2026 and bottomed at $10.0 million in Q2 2022.
• Historically, Other Non-Current Assets has averaged $37.2 million across 5 years, with a median of $39.5 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets jumped 468.18% in 2022, then sank 69.94% in 2025.
• Over 5 years, Other Non-Current Assets stood at $25.0 million in 2022, then soared by 98.4% to $49.6 million in 2023, then increased by 4.84% to $52.0 million in 2024, then fell by 6.35% to $48.7 million in 2025, then rose by 21.77% to $59.3 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $59.3 million, $73.6 million, and $48.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.